2003
DOI: 10.3892/or.10.5.1067
|View full text |Cite
|
Sign up to set email alerts
|

Differential expression of neuropilin-1 in malignant and benign prostatic stromal tissue

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
32
0

Year Published

2004
2004
2019
2019

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 32 publications
(33 citation statements)
references
References 0 publications
1
32
0
Order By: Relevance
“…Accumulating evidence suggests that neuropilin-1 is overexpressed in several cancers and its high expression is correlated with poor prognosis (Ding et al, 2000;Kawakami et al, 2002;Roche et al, 2002;Vanveldhuizen et al, 2003;Broholm and Laursen, 2004;Fukahi et al, 2004;Li et al, 2004;Osada et al, 2004;Parikh et Figure 8 Semaphorin3A (Sema3A) expression in human glioblastoma multiformes (GBMs). (a) Immunohistochemical analysis of Sema3A in human GBM tissue.…”
Section: Discussionmentioning
confidence: 99%
“…Accumulating evidence suggests that neuropilin-1 is overexpressed in several cancers and its high expression is correlated with poor prognosis (Ding et al, 2000;Kawakami et al, 2002;Roche et al, 2002;Vanveldhuizen et al, 2003;Broholm and Laursen, 2004;Fukahi et al, 2004;Li et al, 2004;Osada et al, 2004;Parikh et Figure 8 Semaphorin3A (Sema3A) expression in human glioblastoma multiformes (GBMs). (a) Immunohistochemical analysis of Sema3A in human GBM tissue.…”
Section: Discussionmentioning
confidence: 99%
“…The NRP-1 is a transmembrane receptor glycoprotein whose expression is known to be increased during the progression of breast, prostate, and lung tumors (Soker et al, 1998;Stephenson et al, 2002;Lantuejoul et al, 2003;Vanveldhuizen et al, 2003). The NRP-1 serves as a vascular endothelial growth factor (VEGF) coreceptor and enhances VEGF receptor 2 (VEGFR2)/kinase insert domain-containing receptor (KDR) binding, tumor angiogenesis, and progression (Soker et al, 1998;Miao et al, 2000).…”
Section: Discussionmentioning
confidence: 99%
“…130 They are expressed on different types of tumor cells, 131 and tumor NRP1 levels correlate with advanced disease and prognosis in certain cancers, such as prostate and lung cancer. [132][133][134] A preclinical study indicates that a monoclonal antibody blocking the binding of VEGF to NRP1 (αNRP1 VEGF ) inhibits tumor growth. Upon combination with anti-VEGF, tumor growth was inhibited more, 131,135 raising the question whether αNRP1 VEGF may perhaps inhibit other ligands, such as PlGF, HGF, FGFs, and so on.…”
Section: Inhibiting Vessel Maturation or Lymphangiogenesis By Blockinmentioning
confidence: 99%